BOAN BIOTECH

6955
3.1050.16% ( +0.005 )
Delay Closed: Nov 16, 16:08:11

Overview

BOAN BIOTECH (6955)

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo...

Open
3.165
High
3.165
Low
2.985
Prev. Close
3.100
Volume
428.40K
Turnover
1.30M
Avg Price
3.042
Bid/Ask Ratio
-60.66%
Amplitude
5.81%
52wk High
11.200
Volume Ratio
0.06
Turnover Ratio
0.07%
52wk Low
2.400
HK Mkt Cap
1.91B
Market CapHKD
1.91B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.181
EPSDynamic
-0.311
EPSStatic
--
BVPS
4.99
P/B
0.62
HK Shares
613.63M
Dividend YieldTTM
--
DividendTTM
--
Shares
613.63M
Min lot size
200
Currency
HKD

BOAN BIOTECH Analyst Rating

View more

Forecast & Rating

Jul 25, 2025
Price forecast
HK$10.46236.77%
Forecast & RatingHold
1analysts
  • Strong buy0.00%
  • Buy0.00%
  • Hold100.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Shandong Boan Biotechnology (6955.HK) staged a rally from a low open, surging in the afternoon session to close up 7.14% at HKD 5.10, driven by positive clinical and licensing news. The company received CDE approval for a Phase II lung cancer trial of a novel immunotherapy combo, while its dulaglutide injection was licensed in the US and two denosumab biosimilar BLAs were submitted to the US FDA, marking key R&D milestones. However, fundamentals remain under pressure: Q4 2025 revenue rose 12.59% YoY to HKD 217.6 million, but net profit swung to a loss of HKD 7.43 million, with EPS down 218.36% YoY. The stock is still 74.37% below its 52-week high of HKD 19.9 and down 37.8% YTD; while it has reclaimed the 20-day MA (HKD 4.828), it remains well below the 60-day MA (HKD 5.985), highlighting persistent valuation concerns.

News